New test may help more couples understand why they experience multiple miscarriages

April 09, 2020

Philadelphia, April 9, 2020 - Approximately five percent of women experience two or more miscarriages, a condition known as recurrent pregnancy loss (RPL). Although genetic testing is important for evaluating RPL, current tests have revealed shortcomings in clinical practice. A report in The Journal of Molecular Diagnostics, published by Elsevier, describes a new high-resolution melting analysis-based test (HRM) that is accurate, rapid, cheap, and easy to perform. When used prior to other tests, it improved cost-effectiveness by 30 percent, an important consideration in areas with limited healthcare resources.

"We speculated that the cost of genetic tests such as chromosomal microarray (CMA) or next-generation sequencing (NGS) will remain high enough to hinder their acceptance as affordable detection methods for RPL evaluation in underdeveloped regions," explained lead investigator Prof. Qiwei Guo, United Diagnostic and Research Center for Clinical Genetics, Women and Children's Hospital, School of Medicine and School of Public Health at Xiamen University, Xiamen, China. "Inspired by the success of prenatal screening and diagnosis for Down syndrome, we hypothesized that a well-accepted screening method like HRM combined with a diagnostic method (CMA or NGS) would advance the clinical practice of genetic testing for products of conception (POCs)."

The use of genetic tests for POCs has been limited in underdeveloped regions with large populations due to low test capacity and high cost. Prof. Guo and his co-investigators observed that although most patients with RPL wanted genetic testing, less than 5 percent had the testing performed, primarily because the cost (about US $440) was prohibitive.

HRM is recognized as one of the best screening methods for detecting point mutations and aneuploidy (the presence of an abnormal number of chromosomes in a cell, for example a human cell having 45 or 47 chromosomes instead of the usual 46) for other medical conditions.

Investigators examined 765 miscarriage tissue samples that had undergone karyotyping, the conventional gold standard genetic test for RPL evaluation. Karyotyping shows the number, size, and appearance of the chromosomes, but the process can be labor intensive, time consuming, and susceptible to human error.

Of those 765 samples, approximately 60 percent showed the presence of numerical chromosomal abnormalities (NCAs). Almost two thirds of those with NCAs had the type of abnormalities that could be detected with HRM testing. Samples analyzed with HRM showed a high technical sensitivity (96.1 percent) and specificity (96.3 percent) as well as a high positive predictive value (95.9 percent) for the screening of chromosomal abnormalities.

Results determined that the costs of diagnosing an explained RPL using karyotyping or the HRM test alone were similar. Performing HRM screening before CMA/NGS testing, however, improved cost-effectiveness by approximately 30 percent. The data also suggested that the test was even more cost effective in women 35 years or older because of increased screening sensitivity.

"We suggest that the HRM test could be used as an initial screening tool followed by other diagnostic methods to improve the cost-effectiveness of RPL evaluation or as an alternative genetic test when other methods are unavailable or unaffordable," stated Prof. Guo. He added that another advantage of HRM testing is its high capacity, which is especially important in underdeveloped countries with large populations.

"We believe that identifying the causes of miscarriages not only assists clinicians in genetic counseling and therapeutic management, but also reduces the emotional distress and psychological burden on affected couples," noted Prof. Guo.
-end-


Elsevier

Related Genetic Testing Articles from Brightsurf:

Genetic testing cost effective for newly diagnosed GIST
UC San Diego School of Medicine researchers reported that genetic testing is cost-effective and beneficial for newly diagnosed patients with metastatic gastrointestinal stromal tumors (GIST), a rare type of cancer.

Genetic testing could improve screening for osteoporosis
An international team of scientists has developed a novel genetic measure that could dramatically improve how doctors assess the risk of sustaining a fracture due to osteoporosis or fragility

New recommendations on genetic testing for prostate cancer
Genetic testing for prostate cancer is still not common. New guidelines show why it's important, and which genes to test for.

For acute myeloid leukemia, genetic testing is often worth the wait
New tailored therapies offer exciting prospects for treating acute myeloid leukemia (AML), but taking advantage of them may require waiting a week or more for genetic testing before starting treatment, posing a dilemma for doctors and patients facing this deadly and often fast-moving disease.

Genetic testing among individuals with ASD
Professional medical societies recommend certain genetic tests for individuals with autism spectrum disorder (ASD).

Breast cancer patients to be evaluated for genetic testing
The guidance from the ACMG differs from a consensus guideline issued in February by the American Society of Breast Surgeons, which recommended genetic testing for all newly diagnosed patients with breast cancer.

New technique isolates placental cells for non-invasive genetic testing
A new technique for isolating cells carrying the full fetal genome from cervical swabs could enable doctors to diagnose genetic disorders without using needles to harvest cells from the placenta.

BRCA1/2 genetic testing recommendations still leave issues unresolved
The U.S. Preventive Services Task Force offers new guidelines on BRCA1/2 genetic testing.

Does genetic testing pose psychosocial risks?
For the last quarter century, researchers have been asking whether genetic information might have negative psychosocial effects.

Genetic testing has a data problem; New software can help
As at-home genetic testing becomes more popular, companies are grappling with how to store all the accumulating data and how to process results quickly.

Read More: Genetic Testing News and Genetic Testing Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.